Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Georgia: - Northside Hospital — Atlanta, Georgia
- Northeast Georgia Medical Center Braselton — Braselton, Georgia
- Northside Hospital - Duluth — Duluth, Georgia
- Northeast Georgia Medical Center-Gainesville — Gainesville, Georgia
- Northside Hospital - Gwinnett — Lawrenceville, Georgia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Georgia: - Grady Health System — Atlanta, Georgia
- Emory Proton Therapy Center — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Georgia: - University Cancer & Blood Center (UCBC) - Athens — Athens, Georgia
- Local Institution - Unk052 — Atlanta, Georgia
- Local Institution - 007-786-C — Carrollton, Georgia
- Local Institution - 007-786-A — Cartersville, Georgia
- Local Institution - 007-786-D — Douglasville, Georgia
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Georgia: - University Cancer & Blood Center, LLC — Athens, Georgia
- Emory University School of Medicine- Grady Campus — Atlanta, Georgia
- Winship Cancer Institute, Emory University — Atlanta, Georgia
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Georgia: - Clinical Study Site — Atlanta, Georgia
- Clinical Study Site — Macon, Georgia
- Clinical Study Site — Macon, Georgia
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Georgia: - Winship Cancer Institute — Atlanta, Georgia
- City of Hope National Medical Center, Atlanta Cancer Center — Newnan, Georgia
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Georgia: - Central Georgia Cancer Care — Macon, Georgia
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Georgia: - Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Georgia: - Curtis and Elizabeth Anderson Cancer — Savannah, Georgia
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Georgia: - Winship Cancer Institute (Adults only) — Atlanta, Georgia
- Arthur M. Blank Hospital (Pediatrics) — Atlanta, Georgia
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Georgia: - Research Site — Marietta, Georgia
Phase 3 Recruiting Industry
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Sponsor: AstraZeneca
NCT ID: NCT06417814
Sites in Georgia: - Research Site — Athens, Georgia
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Georgia: - Northwest Georgia Oncology Centers PC — Marietta, Georgia
Phase 3 Recruiting Academic/Other
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Georgia: - Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Georgia: - University Cancer and Blood Center LLC — Athens, Georgia
- Northeast Georgia Medical Center-Gainesville — Gainesville, Georgia
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Georgia: - University Cancer And Blood Center LLC — Athens, Georgia
- Grady Health System Correll Pavilion — Atlanta, Georgia
- Piedmont Healthcare — Atlanta, Georgia
- Piedmont Cancer Institute — Atlanta, Georgia
- Winship Cancer Institute Emory University — Atlanta, Georgia
Phase 2 Recruiting Industry
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT04614103
Sites in Georgia: - Augusta University — Augusta, Georgia
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT06568939
Sites in Georgia: - University Cancer & Blood Center /ID# 270969 — Athens, Georgia
- Northwest Georgia Oncology Centers /ID# 275374 — Marietta, Georgia
- Memorial University Medical Center /ID# 272467 — Savannah, Georgia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Georgia: - Southeastern Regional Medical Center, LLC — Newnan, Georgia
Phase 2 Recruiting Industry
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; th…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT06667908
Sites in Georgia: - Emory University Winship Cancer Institute — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in Georgia: - Research Site 111 — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all …
Sponsor: Chipscreen Biosciences, Ltd.
NCT ID: NCT05271292
Sites in Georgia: - Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults wi…
Sponsor: NiKang Therapeutics, Inc.
NCT ID: NCT06586957
Sites in Georgia: - Emory Winship Cancer Institute — Atlanta, Georgia
- Augusta University — Augusta, Georgia
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT06293898
Sites in Georgia: - Georgia Cancer Center at Augusta University — Augusta, Georgia
Phase 1 Recruiting Industry
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expa…
Sponsor: Amgen
NCT ID: NCT07037758
Sites in Georgia: - Emory University — Atlanta, Georgia